



ABN 53 075 582 740

**ASX ANNOUNCEMENT
16 MAY 2022**

Bionomics Limited to Participate in Upcoming Investor Conferences.

Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (**Bionomics** or **Company**), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Dr Errol De Souza, Executive Chairman of Bionomics, will participate in three upcoming investor conferences:

- Citibank Biotech's Mood Disorders/Mental Health Panel
 - Taking place virtually on May 18th, 2022 at 11:00 am ET
- Berenberg Capital Markets Emerging Biotech Conference
 - Taking place virtually and in-person in San Francisco on May 19th, 2022
- H.C. Wainwright Global Investment Conference
 - Taking place virtually and in-person in Miami Beach from May 23rd - 26th

An audio webcast link for each event, when available, will be posted to Bionomics' website in the Investors-Events and Presentations section.

Released on authority of the Executive Chairman.

FOR FURTHER INFORMATION PLEASE CONTACT:

General:

Ms Suzanne Irwin
Company Secretary
+61 8 8150 7400

CoSec@bionomics.com.au

Investor Relations:

Mr. Connor Bernstein
Vice President, Strategy and Corporate Development
+1 (650) 524-5143

cbernstein@bionomics.com.au

About Bionomics Limited

Bionomics (ASX:BNO, NASDAQ:BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the $\alpha 7$ nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains “forward-looking” statements within the meaning of the U.S. federal securities laws. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements related to the Offering are deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those discussed in this ASX announcement.